Female fertility testing spans a wide range, from urine-based ovulation kits you can buy at a pharmacy to multi-step clinical workups involving blood draws, imaging, and sometimes surgery. No single test captures everything that matters for conception. Instead, testing builds in layers: you start with the simplest and least invasive options, and a clinician adds complexity only when earlier results raise questions or initial attempts at conception have not worked. Understanding what each layer measures, and what it cannot tell you, keeps you from over-interpreting a single number or skipping something that actually matters.
Ovulation Predictor Kits
The most common starting point is a urine-based ovulation predictor kit, or OPK. These strips detect the surge in luteinizing hormone (LH) that typically happens about 24 to 36 hours before you release an egg. You dip a strip in urine daily during the middle of your cycle, and a positive result tells you ovulation is likely imminent, so the next couple of days are your best window for intercourse.
A 2024 study compared five popular OPK brands head to head against blood LH levels and found accuracy rates clustered tightly between about 92% and 97% for detecting the surge. Sensitivity, meaning the ability to catch a real surge rather than miss it, varied a bit more across brands but all performed reasonably well when used correctly.1PubMed. Similar accuracy and patient experience with different one-step ovulation predictor kits The main pitfall is user error: testing at inconsistent times, drinking too much water beforehand (which dilutes urine), or starting tests too late in the cycle. If you have irregular cycles, it can also be hard to know when to begin testing. OPKs tell you that your body is gearing up to ovulate, but they do not confirm that an egg was actually released.
Confirming Ovulation After the Fact
Knowing that an LH surge happened is useful, but it does not prove ovulation occurred. A small percentage of cycles show an LH surge without a corresponding egg release. That is where progesterone confirmation comes in. After ovulation, the empty follicle transforms into a structure that pumps out progesterone. Detecting that rise means an egg was released.
At-home urine strips now measure pregnanediol-3-glucuronide (PDG), a metabolite your body produces when progesterone levels climb. A pilot study found that these strips had 100% specificity for confirming ovulation and sensitivity between 85% and 88%, depending on cycle characteristics.2BMJ Open. Pilot observational prospective cohort study on the use of a novel home-based urinary pregnanediol 3-glucuronide (PDG) test to confirm ovulation when used as adjunct to fertility awareness methods (FAMs) stage 1 The threshold on the test strip matters: another trial found that strips calibrated at a lower cutoff caught ovulation in about 82% of cycles compared with only 59% for a higher cutoff.3PubMed Central. Pilot Evaluation of a New Urine Progesterone Test to Confirm Ovulation in Women Using a Fertility Monitor Research using lab-grade analysis of dried urine spots showed that testing over two or three consecutive days dramatically reduced false negatives, bringing the miss rate down to roughly 2–3%.4PubMed. Direct measurement of pregnanediol 3-glucuronide (PDG) in dried urine spots by liquid chromatography-mass spectrometry to detect ovulation In practice, this means if you are using at-home PDG strips, testing for a few days after your expected ovulation gives you the most reliable answer.
Temperature Tracking and Wearables
Basal body temperature (BBT) tracking is one of the oldest fertility awareness methods. After ovulation, your core temperature rises slightly due to progesterone, and you look for that shift on a daily chart. The problem is that traditional BBT taken with a thermometer first thing in the morning is not very sensitive. Wearable devices that continuously measure wrist skin temperature overnight have tried to improve on this, but the trade-offs are real.
A prospective study comparing wrist-worn temperature sensors with traditional BBT found that the wearable was better at catching a real temperature shift, with a sensitivity of about 0.62 versus 0.23 for oral BBT. But it also had more false alarms: a higher false-positive rate meant lower specificity. When either method did detect a shift, the probability that ovulation had actually occurred was similar for both, around 85–86%.5PubMed Central. The Accuracy of Wrist Skin Temperature in Detecting Ovulation Compared to Basal Body Temperature: Prospective Comparative Diagnostic Accuracy Study Both methods also had very low negative predictive values, meaning that not detecting a shift did not reliably rule out ovulation. Temperature tracking works best as a supplementary signal rather than your only ovulation indicator.
The Saliva Ferning Myth
Some products marketed for home fertility testing ask you to look at dried saliva under a small microscope. Near ovulation, rising estrogen can cause saliva to form crystalline “ferning” patterns. A smartphone-based AI system for reading these patterns achieved impressive accuracy in laboratory conditions.6PubMed Central. An inexpensive smartphone-based device for point-of-care ovulation testing However, when tested in real-world use, the story changes considerably. A clinical study evaluating ferning alongside other home methods found that the salivary ferning test detected ovulation on the correct day only about 37% of the time, and nearly 59% of results were uninterpretable.7PubMed. Efficacy of methods for determining ovulation in a natural family planning program Food, drink, toothpaste, and hydration all affect the sample. Until the technology matures further, ferning kits remain more novelty than reliable clinical tool.
At-Home AMH Blood Tests
Anti-Müllerian hormone (AMH) is produced by small, growing follicles in the ovaries and is widely used as a marker for ovarian reserve, a rough gauge of how many eggs you have left.8PubMed Central. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function Several companies now offer finger-prick AMH tests you can do at home, mailing a small blood sample to a lab. A head-to-head comparison study found that one type of at-home collection device (a micro-sampling “TAP” device) matched standard venous blood draws almost perfectly, with sensitivity and specificity both at 100%.9PubMed Central. Evaluation of at-home serum anti-Müllerian hormone testing: a head-to-head comparison study Dried blood spot methods and finger-stick capillary samples have also shown strong correlation with lab-drawn venous samples.10Human Reproduction. Quantification of anti-Müllerian hormone (AMH) in dried blood spots: validation of a minimally invasive method for assessing ovarian reserve11Clinical and Experimental Reproductive Medicine. Comparison of serum anti-Müllerian hormone concentrations measured in capillary fingerstick and venous samples from Korean reproductive-aged women The accuracy of the collection method is generally good, but the interpretation of your result deserves caution.
What AMH Does and Does Not Tell You
AMH is one of the most misunderstood fertility numbers. A low result can be alarming, but it is not a straightforward prediction of whether you will get pregnant naturally. AMH reflects follicle quantity, not egg quality, and those are very different things.
A prospective cohort study in healthy women in their mid-twenties found that those with low AMH (in the bottom fifth) did not have reduced chances of conceiving compared to women with average AMH levels.12PubMed. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study Another study in infertile women found that AMH levels below 0.7 ng/mL did not significantly increase the odds of unexplained infertility versus male-factor infertility, suggesting low AMH alone was not driving the fertility problem.13PubMed Central. Ovarian reserve does not influence natural conception: insights from infertile women Among younger infertile women trying timed intercourse, pregnancy rates were similar for normal AMH and low AMH groups (roughly 44% versus 41%), though women with very low AMH took significantly longer to conceive.14PubMed Central. The likelihood of achieving pregnancy through timed coitus in young infertile women with decreased ovarian reserve
Where AMH shines is in predicting how you will respond to ovarian stimulation during IVF. A low AMH warns your doctor you may produce fewer eggs per cycle, which affects medication dosing and expectations. Age itself remains a stronger predictor of egg quality and embryo viability than any hormone level or follicle count.15PubMed Central. Age as a Predictor of Embryo Quality Regardless of The Quantitative Ovarian Response So if you get an at-home AMH result that looks low, that number deserves a conversation with a reproductive specialist rather than panic. It is one data point, not a verdict.
The Day 3 Blood Panel
When a fertility specialist starts a clinical workup, a common first step is blood drawn on cycle day 2 or 3 (counting the first day of your period as day 1). This panel typically includes FSH, estradiol, and often AMH as well. The timing matters because hormone levels fluctuate dramatically across the menstrual cycle, and early-follicular-phase values give the most standardized snapshot.
FSH on day 3 has been used as an ovarian reserve indicator since the late 1980s. In one of the foundational studies, women undergoing IVF who had low day-3 FSH (under 15 mIU/mL) had ongoing pregnancy rates of 17% per attempt, while those with high FSH (over 25 mIU/mL) had rates of only 3.6%.16PubMed. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome Estradiol adds a layer of nuance: even when FSH looks normal, an elevated day-3 estradiol predicts a poor response to stimulation, with one study finding a 56% cycle cancellation rate in those with high estradiol versus 13% in those with low levels.17PubMed. Elevated levels of basal estradiol-17beta predict poor response in patients with normal basal levels of follicle-stimulating hormone undergoing in vitro fertilization
AMH has increasingly complemented or partly replaced FSH in this assessment because it correlates more strongly with the actual number of small follicles visible on ultrasound. A study directly comparing all the day-3 markers found that AMH correlated with antral follicle count far better than FSH, estradiol, or inhibin B.18Human Reproduction. Serum anti‐Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3 Most clinics now run AMH alongside the traditional day-3 panel for a more complete picture.
Thyroid and Prolactin Screening
Fertility workups almost always include thyroid-stimulating hormone (TSH) and prolactin, two hormones that sit outside the reproductive axis but can silently derail it. Both underactive and overactive thyroid conditions disrupt menstrual cycles and ovulation. Elevated prolactin, which can occur on its own or as a consequence of hypothyroidism, suppresses ovulation as well. A study comparing infertile women to fertile controls found a higher prevalence of both hypothyroidism and elevated prolactin in the infertile group.19PubMed Central. Correlation of Prolactin and Thyroid Hormone Concentration with Menstrual Patterns in Infertile Women Research in women with absent periods has confirmed the interplay: those with elevated prolactin tended to have lower free thyroid hormone levels, and prolactin correlated positively with TSH.20PubMed Central. Association of Thyroid Profile and Prolactin Level in Patient with Secondary Amenorrhea
The good news is that both conditions are treatable. Thyroid medication or a prolactin-lowering drug often restores regular ovulation without any further intervention. That is why this screening is so worthwhile: it catches fixable problems before you move on to expensive or invasive procedures.
Mid-Luteal Progesterone Blood Draw
If your doctor wants lab confirmation that you ovulated in a given cycle, the standard approach is a blood progesterone test drawn about a week after suspected ovulation, usually around cycle day 21 in a textbook 28-day cycle. Classic research established that a serum progesterone level of 3 ng/mL or higher, measured between 4 and 11 days before the next period, is presumptive evidence of ovulation.21American Journal of Obstetrics and Gynecology. Single luteal phase serum progesterone assay as an indicator of ovulation More recent work has refined this, finding that a random serum progesterone of 5 ng/mL or above confirms ovulation with about 98% specificity.22PubMed. Random serum progesterone threshold to confirm ovulation
Timing is the tricky part. If your cycles are longer or shorter than 28 days, “day 21” is the wrong time to draw blood. The test needs to hit the mid-luteal phase, which is roughly a week after you ovulate regardless of how long your cycle is. Using OPK data or tracking apps to time the draw makes this more accurate.
Ultrasound and Antral Follicle Count
A transvaginal ultrasound done early in the cycle lets a clinician count antral follicles, the small fluid-filled sacs that each contain an immature egg. The antral follicle count (AFC) is another measure of ovarian reserve and directly informs how aggressively a clinic will stimulate your ovaries if you pursue IVF.
Three-dimensional ultrasound technology has improved the reliability of these counts. Studies comparing different ultrasound methods found that 3D imaging with automated counting software produced the most reproducible results between different operators.23PubMed. Intraobserver and interobserver reliability of automated antral follicle counts made using three-dimensional ultrasound and SonoAVC Standard 3D ultrasound also showed significantly higher agreement between observers than traditional 2D imaging, with narrower margins of disagreement.24PubMed. Three-dimensional ultrasound improves the interobserver reliability of antral follicle counts and facilitates increased clinical work flow Not every clinic uses 3D technology, but the trend is moving that way. Even with 2D ultrasound, an experienced sonographer produces reliable counts that meaningfully inform treatment planning.
Checking the Tubes
Blocked or damaged fallopian tubes are a major cause of infertility, and you will not know about a blockage from hormone tests alone. The traditional way to check is hysterosalpingography (HSG), an X-ray-based procedure where contrast dye is pushed through the uterus and tubes. If the dye flows freely out the ends, the tubes are open.
HSG is more than just diagnostic. A large randomized trial found that women who had HSG done with oil-based contrast had significantly higher ongoing pregnancy and live birth rates in the months afterward compared with those who received water-based contrast, with roughly 39% versus 29% achieving ongoing pregnancy.25PubMed. Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile Women A meta-analysis confirmed this fertility benefit for oil-based contrast, finding increased rates of clinical pregnancy, ongoing pregnancy, and live birth, with no difference in miscarriage or ectopic pregnancy rates between contrast types.26PubMed Central. Comparison of fertility outcomes between oil‑based and water‑based contrast media during hysterosalpingography: A meta‑analysis The mechanism is not fully understood, but the procedure itself may flush small debris or thin mucus plugs from the tubes.
An increasingly popular alternative is hysterosalpingo-foam sonography (HyFoSy), which uses an ultrasound-visible foam instead of X-ray dye. A systematic review and meta-analysis found no difference between HyFoSy and HSG in their ability to identify tubal patency, with comparable procedure failure rates.27PubMed. Is hysterosalpingo-foam sonography the new gold standard for assessing tubal patency? A systematic review and meta-analysis HyFoSy avoids radiation exposure and is generally reported as less painful, though its agreement with HSG has been characterized as fair to moderate when studies compare the two directly.28PubMed Central. Diagnostic Accuracy Study Comparing Hysterosalpingo-Foam Sonography and Hysterosalpingography for Fallopian Tube Patency Assessment If your clinic offers HyFoSy and you want to avoid X-rays, it is a reasonable option, though HSG with oil-based contrast carries the added potential therapeutic benefit.
When Laparoscopy Enters the Picture
If blood tests, imaging, and a semen analysis all come back normal but pregnancy is still not happening, laparoscopy may be recommended. This is a minimally invasive surgery under general anesthesia where a thin camera is inserted through a small incision near the navel to directly visualize the pelvic organs. It can reveal problems invisible to ultrasound and HSG, such as endometriosis or pelvic adhesions.
A study of 138 women diagnosed with unexplained infertility who underwent laparoscopy found that nearly half actually had identifiable pathology, most commonly minor endometriosis, that had been missed by non-invasive workup.29PubMed Central. Laparoscopy for the treatment of unexplained infertility Because laparoscopy carries surgical risks and requires recovery time, it typically comes late in the evaluation process, reserved for cases where less invasive steps have not provided answers.
Genetic and Chromosomal Screening
Genetic testing is not part of a standard initial fertility workup for most couples, but it becomes relevant in specific situations: recurrent pregnancy loss, primary amenorrhea (never having had a period), premature ovarian insufficiency, or when assisted reproduction is planned. Karyotype analysis (checking the chromosomes of both partners) is recommended in these cases because chromosomal abnormalities are more common in infertile couples than in the general population. A large screening study of over 2,700 infertile couples found abnormal karyotypes in about 1.3% of women and 1.5% of men.30PubMed. Genetic screening in 2,710 infertile candidate couples for assisted reproductive techniques: results of application of Italian guidelines for the appropriate use of genetic tests
For women with premature ovarian insufficiency specifically, screening for the FMR1 gene (associated with fragile X syndrome) is commonly recommended, because FMR1 premutations are an established cause of early ovarian failure. Early genetic identification can sometimes lead to proactive steps like egg freezing before follicle depletion is complete.31Middle East Fertility Society Journal. Genetic screening for infertility: When should it be done? For recurrent miscarriage, karyotyping of both partners is standard, and for conditions like polycystic ovary syndrome, no routine genetic test is currently recommended.
The Endometrial Microbiome
A newer and still-evolving area of fertility testing looks at the bacterial community living inside the uterus. Research has found that the composition of endometrial bacteria correlates with reproductive outcomes in infertile patients. Specifically, a uterine lining dominated by Lactobacillus was consistently associated with live births, while profiles containing a mix of other bacteria were linked to unsuccessful outcomes.32PubMed Central. Endometrial microbiota composition is associated with reproductive outcome in infertile patients Some fertility clinics now offer endometrial microbiome testing, marketed under various brand names, usually as an add-on before embryo transfer.
The evidence here is still maturing. Association does not prove that altering the microbiome improves pregnancy rates, and the clinical tests have not been validated in large randomized trials. If your clinic recommends this test, it is worth asking what they plan to do with the result and whether that intervention has strong evidence behind it.
Do Not Skip the Semen Analysis
One of the biggest mistakes in a fertility workup is focusing exclusively on the female partner. Male factors are the sole cause in about 30% of infertile couples and a contributing factor in another 20%.33PubMed Central. Male factor infertility: Initial workup and diagnosis in primary care A semen analysis is inexpensive, non-invasive, and can be done in parallel with the woman’s initial blood work. Waiting until after an extensive and costly female workup to test the male partner wastes time and money. Most guidelines recommend semen analysis as one of the first steps, alongside ovulation assessment and basic hormone screening.
What a Full Workup Costs
Cost is a real barrier that shapes how people approach fertility testing. A U.S. analysis of infertility workup costs found that the average total across all states was roughly $1,559, but this varied dramatically by region and state, ranging from about $800 to $3,000. The Midwest had the highest regional average, and costs correlated with median household income in the area.34PubMed Central. Disparities in infertility workup costs across the United States These figures generally cover the diagnostic phase only: blood panels, ultrasound, HSG, and a semen analysis. They do not include treatment. Insurance coverage varies enormously by state and plan, and many at-home tests are out-of-pocket expenses that may or may not be reimbursed.
If you are paying out of pocket, a reasonable strategy is to start with what you can do at home (OPKs, PDG confirmation strips, possibly an at-home AMH kit) and bring those results to your first specialist appointment. This gives the clinician baseline data without duplicating tests, and it shows you have been tracking your cycles, which can speed up the clinical evaluation.